期刊文献+

紫杉醇抗肿瘤的临床研究进展 被引量:5

原文传递
导出
摘要 为避免和减少紫杉醇在抗肿瘤治疗中的毒副作用,国内外在药物剂型、给药途径和时间以及联合用药等方面开展了广泛的实验室和临床研究。
出处 《滨州职业学院学报》 2008年第3期24-27,共4页 Journal of Binzhou Polytechnic
  • 相关文献

参考文献14

  • 1刘斌.紫杉醇新剂型——紫杉醇脂质体(力扑素)临床应用观察[J].中国医院用药评价与分析,2007,7(1):59-60. 被引量:25
  • 2梅林,孙洪范,宋存先.紫杉醇制剂研究进展[J].中国药学杂志,2006,41(18):1366-1370. 被引量:16
  • 3董洪敏,金风,吴伟莉,欧阳金陵,陈海霞.紫杉醇联合顺铂治疗晚期鼻咽癌的临床研究[J].四川肿瘤防治,2005,18(1):15-17. 被引量:2
  • 4王方聚,王淑静,朱永峰.紫杉醇联合卡铂治疗小细胞肺癌的临床效果[J].实用医药杂志,2005,22(2):129-129. 被引量:5
  • 5Yoshida T,,Yoshikawa T,Tsuburava A,et al.Feasibility study of biweekly CPT-11plus CDDP for-S-1-and paclitaxel-refractory,metastatic gastric cancer[].An-ticancer Res.2006 被引量:1
  • 6S. S. Feng,L. Mu,K. Y. Win,G. Huang.Nanoparticles of biodegradable polymers for clinical administration of paclitaxel[].Current Medicinal Chemistry.2004 被引量:1
  • 7Fujiwara K,Suzuki S,Ishikawa H, et al.Preliminary toxicity analysis of intraperitoneal carboplatin in combination with intravenous paclitaxel chemotherapy for patients with carcinoma of the ovary, peritoneum, or fallopian tube[].International Journal of Gynecological Cancer.2005 被引量:1
  • 8Goffin,JR,Anderson,IC,Supko,JG,Eder,JPJ,Shapiro,GI,Lynch,TJ,Shipp,M,Johnson,BE,Skarin,AT.Phase I trial of the matrix metalloproteinase inhibitor marimastat combined with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer[].Clinical Cancer Research.2005 被引量:1
  • 9Rothenberg,ML,Liu,PY,Braly,PS,Wilczynski,SP,Hannigan,EV,Wadler,S,Stuart,G,Jiang,C,Markman,M,Alberts,DS.Combined Intraperitoneal and Intravenous Chemotherapy for Women with Optimally Debulked Ovarian Cancer: Results from an Intergroup Phase II Trial[].Journal of Clinical Oncology.2003 被引量:1
  • 10Kita T,Kikuchi Y,Takano M,et al.The effect of single weekly paclitaxel in heavily pretreated patients with recurrent or persistent advanced ovarian cancer[].Gynecologic Oncology.2004 被引量:1

二级参考文献16

  • 1管忠震.鼻咽癌化学治疗的概况[J].癌症,1989,8(2):120-121. 被引量:66
  • 2张湘茹,孙燕.紫杉醇治疗非小细胞肺癌[J].中国新药杂志,1996,5(4):245-248. 被引量:31
  • 3潘启超 胥彬.肿瘤药物学与化学治疗[M](第2版)[M].河南:河南医科大学出版社,2000.518. 被引量:1
  • 4Hainsworth JD,Burris HA,Erland JB,et al. Phase I study of docetaxol administered by weekly infusion inpatients with advanced refractory cancer[J]. JClin oncol, 1998,16:2164 ~ 2168. 被引量:1
  • 5Forastiere AA,Neuberg D.Taylor SG.et al. PhaseⅡ evaluation of Taxol in advanced head and neck cancer: An Eastern Cooperative Oncology group trail[ J]. J Aati Cancer lnst Monogr, 1993,15:181 ~ 184. 被引量:1
  • 6Donebower RC. Rowinsky EK. Paclitaxel[J] .PPO updates, 1994,8(10) :5. 被引量:1
  • 7陈东福 见:谷铣之 段蔚伯.小细胞肺癌的放射治疗[A].见:谷铣之,段蔚伯.肿瘤放射治疗学[C].,2002.642-646. 被引量:1
  • 8Murphy WK,Winrj Fosstllafv. Phase Ⅱ study of taxol in patiens with stage in NSCLC proc. Am Clin Oncol, 1992, 11(3): 294. 被引量:1
  • 9Straubinger RM,Sharma A,Murray M,et al.Novel Taxol formulations:Taxol2containing liposomes[J].J Natl Cancer Inst Monogr,1993,15:69. 被引量:1
  • 10Sharma A,Mayhew E,Bolicsak L,et al.Activity of paclitaxel liposomeformulations against human ovarian tumor xenografts[J].Int J Cancer,1997,71(1):103. 被引量:1

共引文献43

同被引文献68

引证文献5

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部